Current Report Filing (8-k)
May 11 2022 - 4:13PM
Edgar (US Regulatory)
0001130166
false
0001130166
2022-05-11
2022-05-11
0001130166
us-gaap:CommonStockMember
2022-05-11
2022-05-11
0001130166
us-gaap:PreferredStockMember
2022-05-11
2022-05-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 11, 2022
CYCLACEL
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
0-50626 |
|
91-1707622 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
(Address of principal executive offices and
zip code)
Registrant’s telephone number, including
area code: (908) 517-7330
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| ¨ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
CYCC |
The Nasdaq Stock Market LLC |
Preferred Stock, $0.001 par value |
CYCCP |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 |
Results of Operations and Financial Condition. |
The information set forth
under this “Item 2.02. Results of Operations and Financial Condition,” including the exhibit attached hereto, shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference
in such filing.
Attached as Exhibit 99.1 is
a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the “Company”), dated May 11, 2022, announcing certain
financial results for the first quarter ended March 31, 2022.
The Company will conduct a
conference call to review its financial results on May 11, 2022, at 4:30 p.m., Eastern Time.
Item 9.01 |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
CYCLACEL PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Paul McBarron |
|
Name: |
Paul McBarron |
|
Title: |
Executive Vice President-Finance, |
|
|
Chief Financial Officer and Chief Operating Officer |
Date: May 11, 2022
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Apr 2023 to Apr 2024